The escalating standoff in the Strait of Hormuz has disrupted pharmaceutical supply chains, placing the U.S. generic drug supply on high alert.
Industry analysts warn that a looming wave of shortages could emerge, echoing some concerns recently highlighted by Fierce Pharma. This alert stems from a risk assessment by the U.S. Pharmacopeia, a global non-profit that sets quality standards for medicines and food ingredients across more than 150 countries.
Geopolitical Escalation Disrupted Drug Supply Chain
Escalating tensions between the U.S., Israel and Iran have renewed concerns about the vulnerability of global pharmaceutical supply chains tied to the Strait of Hormuz. While the waterway is best known as a critical energy corridor, it also serves as a vital transit hub for chemical ingredients, pharmaceutical precursors and finished generics that sustain the U.S. healthcare system.
The pharmaceutical industry relies heavily on petroleum-derived products to manufacture medicine. However, the ongoing threat of Strait closures has severely hindered global oil and petroleum transport by both air and sea.
The industry’s reliance on a limited set of countries for key inputs is now being tested by the escalating conflict. The U.S. Pharmacopeia identifies this geographic concentration as a core systemic risk within the industry.
Active drug shortages are trending upward. Data from the American Society of Health-System Pharmacists show that active drug shortages hit a peak of 223 in March. The most acute pressure is being felt in injectables, a category that includes life-saving antimicrobials, chemotherapy agents, and emergency autonomic drugs.
“These disruptions severely impact patient care, leading to treatment delays and increased healthcare costs,” noted the U.S. Pharmacopeia in its recent video analysis of supply chain vulnerabilities.
To mitigate this risk, the U.S. Department of Health and Human Services advises hospitals and distributors to maintain buffer inventories of essential medications. Paradoxically, the greatest threat to stability may be the reaction to the shortages themselves.
“What could cause challenges is people buying differently than they did for fear of those changes,” warned Laura Bray, founder of Angels for Change, in a recent interview with Healthcare Brew. “That [panic-buying] could be immediate and severe.”
The Logistics Collapse
Halted traffic has disrupted the flow of raw materials, particularly for India, the primary manufacturer of generics for the U.S. market. The country supplies roughly 35% of all active pharmaceutical ingredients used globally.
Before the current escalation, the Strait of Hormuz was a high-traffic corridor with vessel volume exceeding 120 ships per day. Traffic through the Strait of Hormuz plummeted by roughly 70% following the initial military escalation, as reported by maritime trade risk analysts.
Now, that flow has been strangled. Data from the Center for Strategic and International Studies (CSIS) reveals a staggering decline. By late April, daily transits had fallen to just 24 vessels.
When maritime routes are disrupted, air freight has long served as a backup. That option, however, is increasingly unreliable as a safety valve.
“Air freight capacity is highly sensitive to airspace restrictions, rerouting, and surcharges,” according to Josh Medow, CEO of Mercury Shipping. “These pressures are already evident in parts of the Middle East, where reduced passenger flights have constrained cargo space.”
The current standoff is more than a regional conflict. It is a stress test for the globalized pharmaceutical supply chain.
The Fragility Of Profitability In A Competitive Market
Geopolitical Tensions Trigger A Profitability Shock
Generic drug makers compete aggressively on price. These firms operate on margins far thinner than those of branded pharmaceutical giants. This economic model has lowered the cost of life-saving medicine worldwide, but it has created a highly sensitive supply chain.
Marta Wosińska, a senior fellow at the Brookings Institution, notes that these razor-thin margins make the current system unsustainable. She explains that low profitability directly contributes to quality lapses and chronic shortages. These financial pressures prevent companies from modernizing factories or maintaining robust supply chains.
When global costs suddenly spike, these companies have minimal room to absorb the costs. However, industry proponents suggest this lean model is the only way to ensure global access to affordable medicines.
“Ultimately, generic drug competition generates billions of dollars in savings each year” wrote Susan Rosencrance, former acting director at the FDA’s Office of Generic Drugs, in a 2022 report.
The Association for Accessible Medicine reported that the generic market generated $467 billion in savings for the U.S. healthcare system in 2024.
Shifting toward higher-priced “resilient” supply chains could place a significant financial burden on public health budgets and uninsured patients.
Conflict Tests A Thin Model
These vulnerabilities are now highly visible as geopolitical instability disrupts global trade. The ongoing conflict in one of the world’s most active maritime corridors has driven up the cost of transporting both pharmaceutical ingredients and finished medicines.
Maritime insurers have sharply increased war-risk premiums. New insurance advisories have identified the Persian Gulf, Iran and waters near Pakistan as elevated-risk zones. Maritime insurers have recently designated portions of the Persian Gulf, Gulf of Oman, Iranian waters, and approaches near the Iran–Pakistan maritime boundary as elevated war-risk zones.
Howden Re, a London-based risk advisory firm, reports that war-risk premiums on some routes have surged by 1,000%. Some firms have withdrawn coverage entirely, while others have adopted a strict “client-by-client” approach.
Severe disruptions in regional airspace have led to widespread reroutes, with some risk databases advising carriers to avoid multiple high-traffic routes.
Industry experts are now watching how these logistical changes will affect U.S. generic drug prices by mid-summer. In the U.K., prices for certain generics have increased by up to 30%.
The Push To Fortify Internal Supply
The United States maintains a massive domestic hydrocarbon and petrochemical base that could, in theory, anchor a self-sufficient pharmaceutical industry.
But over the past several decades, drugmakers shifted much of their generic drug manufacturing and active pharmaceutical ingredients overseas to capitalize on lower labor and regulatory costs.
Now, as rising geopolitical instability fractures global trade, there are renewed calls to rebuild America’s domestic manufacturing capacity. In April 2026, the Trump administration proposed steep tariffs on imported pharmaceuticals as part of a broader effort to reshore manufacturing.
The proposal targets a 100% duty on many imported medications. But companies that commit to an approved U.S. onshoring plan by January 20, 2029, can qualify for reduced tariff rates.
Supporters claim the strategy could strengthen supply chain security and reduce dependence on foreign manufacturers. They argue that today’s low generic drug prices fail to reflect the risks associated with shortages, quality failures, and concentrated overseas production.
The Center for Strategic and International Studies cautions that expanding domestic production for generics and APIs would likely drive up drug costs. The organization notes that reshoring requires massive capital and entails significantly higher operating expenses.
Since 9 in 10 prescriptions filled in the United States are generics, changes in production and pricing will affect nearly every American household.
